Table 2– Single and multiple mutation prevalence in EUELC patients
GeneAnalysed samples nStatusPatients n (%)
TP53250Wild-type129 (51.6)
Mutant (exons 4-9)121 (48.4)
KRAS249Wild-type203 (81.5)
Mutant (codon 12)46 (18.5)
TP53 wild-type35 (76.1)
TP53 mutant11 (23.9)
EGFR#130Wild-type113 (86.9)
Mutant17 (13.1)
TP53 wild-type11 (64.7)
TP53 mutant6 (35.3)
KRAS wild-type16 (95)
KRAS mutant1 (5)
  • #: the group of cases analysed includes only adenocarcinoma; : where 17 is 100%.